

Patient NAME : Mrs Dummy PI61A	Report STATUS : Final Report
DOB/Age/Gender : 30 Y/Female	Barcode NO : ZF584783
Patient ID / UHID : 10671092/OF10671092	Sample Type : FLUORIDE F
Referred BY : Self	Report Date : Dec 06, 2024, 12:49 PM.
Sample Collected : Dec 06, 2024, 10:34 AM	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

Polycystic Ovary Syndrome (PCOS) Panel - Essential

Glucose Fasting

Glucose Fasting <i>Hexokinase</i>	88.0	mg/dL	70 - 100
--------------------------------------	------	-------	----------

Interpretation:

Status	Fasting plasma glucose in mg/dL
Normal	<100
Impaired fasting glucose	100 - 125
Diabetes	≥126

Reference : American Diabetes Association

Comment :

Blood glucose determinations in commonly used as an aid in the diagnosis and treatment of diabetes. Elevated glucose levels (hyperglycemia) may also occur with pancreatic neoplasm, hyperthyroidism, and adrenal cortical hyper function as well as other disorders. Decreased glucose levels (hypoglycemia) may result from excessive insulin therapy insulinoma, or various liver diseases.

Note

- 1.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL or a random / 2 hour plasma glucose value of > or = 200 mg/dL with symptoms of diabetes mellitus.
- 2.Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis.

Booking Centre :- REDCLIFFE - ILC NOIDA

Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301



Patient NAME : Mrs Dummy PI61A	Report STATUS : Final Report
DOB/Age/Gender : 30 Y/Female	Barcode NO : ZF584784
Patient ID / UHID : 10671092/OF10671092	Sample Type : Serum
Referred BY : Self	Report Date : Dec 06, 2024, 12:50 PM.
Sample Collected : Dec 06, 2024, 10:34 AM	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

Lipid Profile

Total Cholesterol <i>Enzymatic - Cholesterol Oxidase</i>	147.0	mg/dL	<200
Triglycerides <i>Colorimetric - Lip/Glycerol Kinase</i>	98.0	mg/dL	<150
HDL Cholesterol <i>Phosphotungstic acid- Enzymatic</i>	45.0	mg/dL	> 40
Non HDL Cholesterol <i>Calculated</i>	102	mg/dL	<130
LDL Cholesterol <i>Calculated</i>	82.4	mg/dL	<100
V.L.D.L Cholesterol <i>Calculated</i>	19.6	mg/dL	< 30
Chol/HDL Ratio <i>Calculated</i>	3.27	Ratio	-
HDL/ LDL Ratio <i>Calculated</i>	0.55	Ratio	-
LDL/HDL Ratio <i>Calculated</i>	1.83	Ratio	-

Interpretation:

Lipid level assessments must be made following 9 to 12 hours of fasting, otherwise assay results might lead to erroneous interpretation. NCEP recommends of 3 different samples to be drawn at intervals of 1 week for harmonizing biological variables that might be encountered in single assays.

National Lipid Association Recommendations (NLA-2014)	Total Cholesterol (mg/dL)	Triglyceride (mg/dL)	LDL Cholesterol (mg/dL)	Non HDL Cholesterol (mg/dL)
Optimal	<200	<150	<100	<130
Above Optimal			100-129	130 - 159
Borderline High	200-239	150-199	130-159	160 - 189
High	>=240	200-499	160-189	190 - 219
Very High	-	>=500	>=190	>=220

HDL Cholesterol	
Low	High
<40	>=60

Risk Stratification for ASCVD (Atherosclerotic Cardiovascular Disease) by Lipid Association of India.

Risk Category	A. CAD with > 1 feature of high risk group
Extreme risk group	B. CAD with >1 feature of very high risk group of recurrent ACS (within 1 year) despite LDL-C <or = 50 mg/dl or poly vascular disease
Very High Risk	1.Established ASCVD 2.Diabetes with 2 major risk factors of evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia

Booking Centre :- REDCLIFFE - ILC NOIDA

Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301



Patient NAME : Mrs Dummy PI61A	Report STATUS : Final Report
DOB/Age/Gender : 30 Y/Female	Barcode NO : ZF584784
Patient ID / UHID : 10671092/OF10671092	Sample Type : Serum
Referred BY : Self	Report Date : Dec 06, 2024, 12:50 PM.
Sample Collected : Dec 06, 2024, 10:34 AM	

Test Description	Value(s)	Unit(s)	Reference Range
High Risk	1. Three major ASCVD risk factors 2. Diabetes with 1 major risk factor or no evidence of end organ damage 3. CHD stage 3B or 4. 4 LDL >190 mg/dl 5. Extreme of a single risk factor 6. Coronary Artery Calcium - CAC > 300 AU 7. Lipoprotein a >= 50 mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors			
1. Age >=45 years in Males & >= 55 years in Females	3. Current Cigarette smoking or tobacco use		
2. Family history of premature ASCVD	4. High blood pressure		
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by Lipid Association of India in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal <OR = 30)	<80 (Optional goal <OR = 60)	>OR = 50	>OR = 80
Extreme Risk Group Category B	>OR = 30	>OR = 60	> 30	> 60
Very High Risk	<50	<80	>OR = 50	>OR = 80
High Risk	<70	<100	>OR = 70	>OR = 100
Moderate Risk	<100	<130	>OR = 100	>OR = 130
Low Risk	<100	<130	>OR = 130*	>OR = 160

* After an adequate non-pharmacological intervention for at least 3 months.

References : Management of Dyslipidaemia for the Prevention of Stroke : Clinical practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology,2022,20,134-155.

Booking Centre :- REDCLIFFE - ILC NOIDA

Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301



Patient NAME : Mrs Dummy PI61A	Report STATUS : Final Report
DOB/Age/Gender : 30 Y/Female	Barcode NO : ZF584784
Patient ID / UHID : 10671092/OF10671092	Sample Type : Serum
Referred BY : Self	Report Date : Dec 06, 2024, 12:51 PM.
Sample Collected : Dec 06, 2024, 10:34 AM	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

TSH 3rd Generation

Thyroid Stimulating Hormone (Ultrasensitive) Chemiluminescence Immuno Assay (CLIA)	3.14	µIU/mL	0.4 - 4.2
---	------	--------	-----------

Interpretation:

Pregnancy	Reference ranges TSH
1 st Trimester	0.1 - 2.5
2 ed Trimester	0.2 - 3.0
3 rd Trimester	0.3 - 3.0

Note:
TSH levels are subject to circadian variation, reaching peak levels between 2-4 am. and at a minimum between 6-10 pm. The variation is of 50 %, hence time of the day has influence on the measured serum TSH concentrations.

Clinical Use:

- Diagnose Hypothyroidism and Hyperthyroidism
- Monitor T4 replacement or T4 suppressive therapy
- Quantify TSH levels in the subnormal range

Increased Levels : Primary hypothyroidism, Subclinical hypothyroidis, TSH dependent Hyperthyroidism, Thyroid hormone resistance

Decreased Levels: Grace disease, Autonomous thyroid hormone secretion, TSH deficiency

Booking Centre :- REDCLIFFE - ILC NOIDA

Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301



Patient NAME : Mrs Dummy PI61A	Report STATUS : Final Report
DOB/Age/Gender : 30 Y/Female	Barcode NO : ZF584784
Patient ID / UHID : 10671092/OF10671092	Sample Type : Serum
Referred BY : Self	Report Date : Dec 06, 2024, 12:51 PM.
Sample Collected : Dec 06, 2024, 10:34 AM	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

Prolactin (PRL)

Prolactin ECLIA	14.3	ng/mL	Men 4.04 - 15.2 Women(Not-pregnant)4.79 - 23.3
--------------------	------	-------	---

Interpretation:

- Note:**
1. Since prolactin is secreted in a pulsatile manner and is also influenced by a variety of physiologic stimuli, it is recommended to test 3 specimens at 20-30 minute intervals after pooling.
 2. Major circulating form of Prolactin is a nonglycosylated monomer, but several forms of Prolactin linked with immunoglobulin occur which can give falsely high Prolactin results.
 3. Macroprolactin assay is recommended if prolactin levels are elevated, but signs and symptoms of hyperprolactinemia are absent or pituitary imaging studies are normal

Clinical Use

- Diagnosis & management of pituitary adenomas
- Differential diagnosis of male & female hypogonadism

Increased Levels

- **Physiologic:** Sleep, stress, postprandially, pain, coitus
- **Systemic disorders:** Chest wall or thoracic spinal cord lesions, Primary / Secondary hypothyroidism, Adrenal insufficiency, Chronic renal failure, Cirrhosis
- **Medications:** **Psychiatric medications** like Phenothiazine, Haloperidol, Risperidone, Domperidone, Fluoxetine, Amitriptylene, MAO inhibitors etc.,

Antihypertensives: Alphamethyldopa, Reserpine, Verapamil

Opiates: Heroin, Methadone, Morphine, Apomorphine

Cimetidine / Ranitidine

- Prolactin secreting pituitary tumors: Prolactinoma, Acromegaly
- Miscellaneous: Epileptic seizures, Ectopic secretion of prolactin by non-pituitary tumors, pressure / transection of pituitary stalk, macroprolactinemia
- Idiopathic

Decreased levels

- Pituitary deficiency: Pituitary necrosis / infarction
- Bromocriptine administration
- Pseudohypoparathyroidism

Testosterone Total

Testosterone Total CLIA	28.1	ng/dL	8.4 - 48.1
----------------------------	------	-------	------------

Interpretation:

Age in Years	Reference Ranges ng/dL
Males 20-49	249 - 836

Booking Centre :- REDCLIFFE - ILC NOIDA

Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301



Patient NAME : Mrs Dummy PI61A
DOB/Age/Gender : 30 Y/Female **Report STATUS : Final Report**
Patient ID / UHID : 10671092/OF10671092 **Barcode NO : ZF584784**
Referred BY : Self **Sample Type : Serum**
Sample Collected : Dec 06, 2024, 10:34 AM **Report Date : Dec 06, 2024, 12:51 PM.**

Test Description	Value(s)	Unit(s)	Reference Range
Males ≥ 50 years	193 - 740		
Females 20-49	8.4 - 48.1		
Females ≥ 50	2.9- 40.8		

Reference values for Males (7-18 years) characterized by Tanner Stage

Tanner Stage	5-95th percentiles (ng/dL)
1	2.31 - 30.28
2	3.75 - 282.06
3	8.65 - 681.78
4	17.88 - 785.6
5	13.27 - 906.15

Reference values for females (8-18 years) characterized by Tanner Stage

Tanner Stage	5-95th percentiles (ng/dL)
1	0.58 - 33.17
2	4.33 - 23.07
3	6.92 - 42.97
4	15.29 - 1.86
5	15.00 - 102.38

Note

1. All applications that require measurement of very low level of testosterone (eg hypogonadal men, children, virilization or intersex disorders in women etc) recommended test is Testosterone total, Ultrasensitive
2. LC-MS/MS is the gold standard for steroid hormone assays due to increased sensitivity & specificity as compared to immunoassays

Clinical Use

Assessment of testicular function in males

Increased levels

1. Precocious puberty (Males)
2. Androgen resistance
3. Testotoxicosis
4. Congenital Adrenal Hyperplasia

Decreased levels

1. Delayed puberty (Males)
2. Gonadotropin deficiency
3. Testicular defects
4. Systemic diseases

Booking Centre :- REDCLIFFE - ILC NOIDA

Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301



Patient NAME : Mrs Dummy PI61A	Report STATUS : Final Report
DOB/Age/Gender : 30 Y/Female	Barcode NO : ZF584784
Patient ID / UHID : 10671092/OF10671092	Sample Type : Serum
Referred BY : Self	Report Date : Dec 06, 2024, 12:51 PM.
Sample Collected : Dec 06, 2024, 10:34 AM	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

LH / FSH Ratio

Luteinising Hormone-LH <i>CMIA</i>	9.2	mIU/mL	Follicular Phase 1.80 - 11.78 Mid-Cycle Peak 7.59 - 89.08 Luteal Phase 0.56 - 14.00 Postmenopausal Females Without HRT 5.16 - 61.99
Follicle Stimulating Hormone-FSH <i>CMIA</i>	7.8	mIU/mL	Normally Menstruating Females Follicular Phase 3.03 - 8.08 Mid-Cycle Peak 2.55 - 16.69 Luteal Phase 1.38 - 5.47 Postmenopausal Females 26.72 - 133.41
LH / FSH Ratio	1.18		

Interpretation:

- Ratio of LH to FSH > 2.50 indicates the presence of PCOS.
- Polycystic Ovary Syndrome (PCOS) is a complex syndrome and each of the clinical phenotype is associated with different patterns of steroid hormones. It is likely that simultaneous measurement of multiple androgens (steroid/androgen profiling with highly specific and sensitive method LC-MS/MS) be more sensitive for detecting PCOS-related androgen excess and for predicting metabolic risk.
- Women with Non-classical Congenital Adrenal Hyperplasia (NC-CAH) due to 21-hydroxylase deficiency and women with PCOS have similar clinical presentation, with hyperandrogenism, oligomenorrhea, and polycystic ovaries. The screening tool to distinguish NC-CAH from PCOS is the basal 17-OHP levels and the ACTH stimulation test.

Comments:

Polycystic Ovarian Syndrome (PCOS) affects 5-10% of women of reproductive age, making it the most common endocrine disorder of women in this age group. It is characterized by amenorrhea, hirsutism and infertility. It is caused by a complex interaction of abnormalities in gonadotropins, androgens & estrogens. Insulin resistance and hyperinsulinemia contribute significantly to its pathophysiology. Although PCOS is associated with hyperandrogenism & infertility early in life, it is a harbinger of a lifelong condition that can lead to serious sequelae such as Endometrial or Ovarian cancer, Diabetes mellitus & Coronary artery disease. Thus, it is crucial to diagnose PCOS early in its course not only to recognize but also to delay or arrest its metabolic sequelae

Clinical use :

- In Diagnosis of gonadal dysfunction and management of infertility
- Increased level : Primary hypogonadism
Decreased level :
 - Hypothalamic GnRH deficiency
 - Hypopituitarism

*** End Of Report ***

Booking Centre :- REDCLIFFE - ILC NOIDA

Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301



Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

DISCLAIMER

This is a sample report provided for demonstration purposes only and does not represent an actual patient report. Test results, reference ranges, methodologies, instrumentation, and report formats may vary depending on the laboratory performing the test. The format and representation shown are indicative of reports generated by the National Reference Laboratory of Redcliffe Labs, Noida. This sample report should not be used for medical interpretation, diagnosis, or treatment decisions.